<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="review-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Front Cell Neurosci</journal-id>
<journal-id journal-id-type="iso-abbrev">Front Cell Neurosci</journal-id>
<journal-id journal-id-type="publisher-id">Front. Cell. Neurosci.</journal-id>
<journal-title-group>
<journal-title>Frontiers in Cellular Neuroscience</journal-title>
</journal-title-group>
<issn pub-type="epub">1662-5102</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">32116556</article-id>
<article-id pub-id-type="pmc">7031676</article-id>
<article-id pub-id-type="doi">10.3389/fncel.2020.00009</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Cellular Neuroscience</subject>
<subj-group>
<subject>Mini Review</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>A Reappraisal of GAT-1 Localization in Neocortex</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Fattorini</surname>
<given-names>Giorgia</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<xref ref-type="author-notes" rid="fn001">
<sup>†</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/7720/overview" xlink:type="simple"></uri>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Melone</surname>
<given-names>Marcello</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<xref ref-type="author-notes" rid="fn001">
<sup>†</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/7970/overview" xlink:type="simple"></uri>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Conti</surname>
<given-names>Fiorenzo</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
<xref ref-type="corresp" rid="c001">
<sup>*</sup>
</xref>
<xref ref-type="author-notes" rid="fn001">
<sup>†</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/6066/overview" xlink:type="simple"></uri>
</contrib>
</contrib-group>
<aff id="aff1"><sup>1</sup><institution>Department of Experimental and Clinical Medicine, Faculty of Medicine and Surgery, Università Politecnica delle Marche</institution>, <addr-line>Ancona</addr-line>, <country>Italy</country></aff>
<aff id="aff2"><sup>2</sup><institution>Center for Neurobiology of Aging, IRCCS INRCA</institution>, <addr-line>Ancona</addr-line>, <country>Italy</country></aff>
<aff id="aff3"><sup>3</sup><institution>Fondazione di Medicina Molecolare, Università Politecnica delle Marche</institution>, <addr-line>Ancona</addr-line>, <country>Italy</country></aff>
<author-notes>
<fn fn-type="edited-by">
<p>Edited by: Eleonora Palma, Sapienza University of Rome, Italy</p>
</fn>
<fn fn-type="edited-by">
<p>Reviewed by: Annalisa Scimemi, University at Albany, United States; Enrico Cherubini, European Brain Research Institute, Italy</p>
</fn>
<corresp id="c001">*Correspondence: Fiorenzo Conti <email>f.conti@univpm.it</email></corresp>
<fn fn-type="other" id="fn001">
<p><sup>†</sup><bold>ORCID</bold> Giorgia Fattorini <ext-link ext-link-type="uri" xlink:href="https://orcid.org/0000-0002-2497-2942">orcid.org/0000-0002-2497-2942</ext-link> Marcello Melone <ext-link ext-link-type="uri" xlink:href="https://orcid.org/0000-0003-4173-0774">orcid.org/0000-0003-4173-0774</ext-link> Fiorenzo Conti <ext-link ext-link-type="uri" xlink:href="https://orcid.org/0000-0001-5853-1566">orcid.org/0000-0001-5853-1566</ext-link></p>
</fn>
</author-notes>
<pub-date pub-type="epub">
<day>13</day>
<month>2</month>
<year>2020</year>
</pub-date>
<pub-date pub-type="collection">
<year>2020</year>
</pub-date>
<volume>14</volume>
<elocation-id>9</elocation-id>
<history>
<date date-type="received">
<day>29</day>
<month>11</month>
<year>2019</year>
</date>
<date date-type="accepted">
<day>13</day>
<month>1</month>
<year>2020</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright © 2020 Fattorini, Melone and Conti.</copyright-statement>
<copyright-year>2020</copyright-year>
<copyright-holder>Fattorini, Melone and Conti</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p>
</license>
</permissions>
<abstract>
<p>γ-Aminobutyric acid (GABA) transporter (GAT)-1, the major GABA transporter in the brain, plays a key role in modulating GABA signaling and is involved in the pathophysiology of several neuropsychiatric diseases, including epilepsy. The original description of GAT-1 as a neuronal transporter has guided the interpretation of the findings of all physiological, pharmacological, genetic, or clinical studies. However, evidence published in the past few years, some of which is briefly reviewed herein, does not seem to be consistent with a neurocentric view of GAT-1 function and calls for more detailed analysis of its localization. We therefore performed a thorough systematic assessment of GAT-1 localization in neocortex and subcortical white matter. In line with earlier work, we found that GAT-1 was robustly expressed in axon terminals forming symmetric synapses and in astrocytic processes, whereas its astrocytic expression was more diffuse than expected and, even more surprisingly, immature and mature oligodendrocytes and microglial cells also expressed the transporter. These data indicate that the era of “neuronal” and “glial” GABA transporters has finally come to a close and provide a wider perspective from which to view GABA-mediated physiological phenomena. In addition, given the well-known involvement of astrocytes, oligodendrocytes, and microglial cells in physiological as well as pathological conditions, the demonstration of functional GAT-1 in these cells is expected to provide greater insight into the phenomena occurring in the diseased brain as well as to prompt a reassessment of earlier findings.</p>
</abstract>
<kwd-group>
<kwd>GAT-1</kwd>
<kwd>GABA transporters</kwd>
<kwd>astrocytes</kwd>
<kwd>oligodendrocytes</kwd>
<kwd>microglia</kwd>
</kwd-group>
<funding-group>
<award-group>
<funding-source id="cn001">Ministero dell’Istruzione, dell’Università e della Ricerca<named-content content-type="fundref-id">10.13039/501100003407</named-content></funding-source>
<award-id rid="cn001">2010JFYFY2_006</award-id>
</award-group>
<award-group>
<funding-source id="cn002">Università Politecnica delle Marche<named-content content-type="fundref-id">10.13039/501100005758</named-content></funding-source>
<award-id rid="cn002">PSA2018</award-id>
</award-group>
</funding-group>
<counts>
<fig-count count="2"></fig-count>
<table-count count="0"></table-count>
<equation-count count="0"></equation-count>
<ref-count count="60"></ref-count>
<page-count count="6"></page-count>
<word-count count="4443"></word-count>
</counts>
</article-meta>
</front>
<body>
<sec id="s1" sec-type="introduction">
<title>Introduction</title>
<p>γ-Aminobutyric acid (GABA) transporter (GAT)-1 is a highly conserved molecule that is encoded by <italic>SLC6A1</italic> and transports GABA in a high-affinity, Na<sup>+</sup>- and Cl<sup>−</sup>-dependent manner (Kanner, <xref ref-type="bibr" rid="B29">1978</xref>; Guastella et al., <xref ref-type="bibr" rid="B24">1990</xref>; Borden, <xref ref-type="bibr" rid="B2">1996</xref>). As the major GABA transporter in the brain, it plays a key role in modulating GABA signaling (Cherubini and Conti, <xref ref-type="bibr" rid="B8">2001</xref>; Scimemi, <xref ref-type="bibr" rid="B53">2014</xref>). Besides being involved in a broad range of brain functions (Cherubini and Conti, <xref ref-type="bibr" rid="B8">2001</xref>; Bragina et al., <xref ref-type="bibr" rid="B5">2008</xref>; Conti et al., <xref ref-type="bibr" rid="B11">2011</xref>; Kinjo et al., <xref ref-type="bibr" rid="B31">2013</xref>; Scimemi, <xref ref-type="bibr" rid="B53">2014</xref>; Savtchenko et al., <xref ref-type="bibr" rid="B50">2015</xref>; Zafar and Jabeen, <xref ref-type="bibr" rid="B59">2018</xref>), GAT-1 has also been implicated in the pathophysiology of a number of neuropsychiatric disorders including anxiety, depression, epilepsy, Alzheimer’s disease, and schizophrenia (Lai et al., <xref ref-type="bibr" rid="B32">1998</xref>; Nägga et al., <xref ref-type="bibr" rid="B46">1999</xref>; Pierri et al., <xref ref-type="bibr" rid="B47">1999</xref>; Sundman-Eriksson and Allard, <xref ref-type="bibr" rid="B55">2002</xref>; Conti et al., <xref ref-type="bibr" rid="B12">2004</xref>; Lewis and Gonzalez-Burgos, <xref ref-type="bibr" rid="B33">2006</xref>; Cope et al., <xref ref-type="bibr" rid="B14">2009</xref>; Bitanihirwe and Woo, <xref ref-type="bibr" rid="B1">2014</xref>; Carvill et al., <xref ref-type="bibr" rid="B7">2015</xref>; Gong et al., <xref ref-type="bibr" rid="B23">2015</xref>; Fuhrer et al., <xref ref-type="bibr" rid="B22">2017</xref>; Mattison et al., <xref ref-type="bibr" rid="B39">2018</xref>).</p>
<p>GABA uptake by GAT-1 is heavily inhibited by cis-3-aminocyclohexane carboxylic acid (ACHC) and, to a lower extent, by 2,4-diaminobutyric acid, but not by β-alanine (Guastella et al., <xref ref-type="bibr" rid="B24">1990</xref>; Keynan et al., <xref ref-type="bibr" rid="B30">1992</xref>; Liu et al., <xref ref-type="bibr" rid="B35">1993</xref>), two features that have often been considered typical of “neuronal” transporters. This view has been bolstered by the demonstration that GAT-1 is strongly expressed in axon terminals (Minelli et al., <xref ref-type="bibr" rid="B44">1995</xref>; Conti et al., <xref ref-type="bibr" rid="B10">1998</xref>)—despite the fact that the same studies also clearly documented an astrocytic localization—and is still widely used to interpret physiological, pharmacological, genetic, and clinical investigations. However, the findings of several studies published in the past few years call for a more detailed analysis of GAT-1 localization.</p>
</sec>
<sec id="s2">
<title>Recent Studies Suggest a Less Simplistic Scenario</title>
<p>After reports of <italic>SLC6A1</italic> variants in patients with myoclonic atonic epilepsy (Dikow et al., <xref ref-type="bibr" rid="B17">2014</xref>; Carvill et al., <xref ref-type="bibr" rid="B7">2015</xref>; Mattison et al., <xref ref-type="bibr" rid="B39">2018</xref>; Cai et al., <xref ref-type="bibr" rid="B6">2019</xref>; Posar and Visconti, <xref ref-type="bibr" rid="B48">2019</xref>), clinical, neurophysiological, and genetic examination of a relatively large cohort of subjects (<italic>n</italic> = 34) bearing <italic>SLC6A1</italic> mutations demonstrated that 97% of them exhibited varying degrees of intellectual disability (ID) and that 91% had been diagnosed with epilepsy (absence, myoclonic, or atonic) based on EEG patterns characterized by irregular, high, ample, generalized spikes, and wave discharges (Johannesen et al., <xref ref-type="bibr" rid="B28">2018</xref>). Notably, more than 60% of these subjects had suffered from moderate or significant ID before epilepsy onset, whereas in a limited number of cases, the ID was not accompanied by epilepsy. Although genetic analysis of the <italic>SLC6A1</italic> variants suggested that the probable disease mechanism was loss of GAT-1 function, assessment of the clinical characteristics associated to them disclosed a wide phenotypic spectrum where the dominant sign, ID, is not quite a “pure” neuronal disorder (Di Marco et al., <xref ref-type="bibr" rid="B16">2016</xref>; Iwase et al., <xref ref-type="bibr" rid="B26">2017</xref>; Maglorius Renkilaraj et al., <xref ref-type="bibr" rid="B37">2017</xref>).</p>
<p>Earlier this year, Inaba et al. (<xref ref-type="bibr" rid="B25">2019</xref>) used a model of chronic brain hypoperfusion to assess the protective effects conferred by the anticonvulsant levetiracetam (LEV) on the white matter of mice subjected to bilateral common carotid artery stenosis (BCAS). They found that LEV: (i) did confer protection against learning and memory impairment and white matter injury; (ii) induced PKA/CREB activation; (iii) raised the number of (GFAP-labeled) astrocytes in a time-dependent manner; (iv) reduced Iba-1-positive (+) microglial cells; and (v) increased oligodendrocytes and their precursor cells (Inaba et al., <xref ref-type="bibr" rid="B25">2019</xref>). According to the evidence published to date, synaptic vesicle protein SV2A is the sole receptor for LEV (Lynch et al., <xref ref-type="bibr" rid="B36">2004</xref>). However, an earlier report that LEV increases GAT-1 expression (Ueda et al., <xref ref-type="bibr" rid="B57">2007</xref>), presumably through protein–protein interactions—as recently shown for other vesicular proteins (Marcotulli et al., <xref ref-type="bibr" rid="B38">2017</xref>)—suggests that at least some of the effects described by Inaba et al. (<xref ref-type="bibr" rid="B25">2019</xref>) might be mediated through GAT-1.</p>
<p>In 1990, Braestrup and colleagues reported that tiagabine [(3R)-1-[4,4-bis(3-methylthiophen-2-yl)but-3-en-1-yl]piperidine-3-carboxylic acid] nipecotic acid] binds GAT-1 with high affinity (Braestrup et al., <xref ref-type="bibr" rid="B4">1990</xref>). Subsequently, after GAT-1 cloning and functional characterization (Guastella et al., <xref ref-type="bibr" rid="B24">1990</xref>), tiagabine was demonstrated to interact specifically with it (Borden et al., <xref ref-type="bibr" rid="B3">1994</xref>; Borden, <xref ref-type="bibr" rid="B2">1996</xref>) and to be a clinically effective antiepileptic drug (Suzdak and Jansen, <xref ref-type="bibr" rid="B56">1995</xref>; Schousboe and White, <xref ref-type="bibr" rid="B52">2009</xref>; Froestl, <xref ref-type="bibr" rid="B21">2011</xref>). The selectivity of tiagabine for GAT-1 confines its action to those regions of the central nervous system where the transporter plays a large role (neocortex, cerebellum, and hippocampus; Jasmin et al., <xref ref-type="bibr" rid="B27">2004</xref>). Tiagabine has also been found to exert antinociceptive, anxiolytic-like, sedative, and antidepressant-like actions (Jasmin et al., <xref ref-type="bibr" rid="B27">2004</xref>; Sałat et al., <xref ref-type="bibr" rid="B49">2015</xref>). Finally, tiagabine monotherapy appears to improve the performance of epilepsy patients on a number of neuropsychological tests (Dodrill et al., <xref ref-type="bibr" rid="B18">1998</xref>), an effect that seems to relate to the report that heterozygous mice show greater learning and memory compared to wild-type and homozygous <italic>GAT-1</italic><sup>−/−</sup> mice (Shi et al., <xref ref-type="bibr" rid="B54">2012</xref>).</p>
<p>In 2015, two articles revived the interest in the effects of tiagabine. In a study of cerebellar GABA signaling using a mouse model of diffuse white matter injury (DWMI), a severe neurological syndrome characterized by hypomyelination and disruption of subcortical white matter development and involving behavioral, cognitive, and motor deficits, Zonouzi et al. (<xref ref-type="bibr" rid="B60">2015</xref>) demonstrated that tiagabine enhances the progression of NG2 (oligodendrocyte precursor) cells and promotes oligodendrogenesis and myelination. The same year, Liu and coworkers documented that in a methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of Parkinson’s disease, tiagabine pretreatment attenuates microglial activation, it confers partial protection on the nigrostriatal axis, and it alleviates motor deficits, but its protective function is abolished in GAT-1 knockout mice challenged with MPTP. The authors also found that tiagabine suppresses microglial activation in mice treated by intranigral lipopolysaccharide infusion, an alternative model of Parkinson’s disease (Liu et al., <xref ref-type="bibr" rid="B34">2015</xref>). Although neither study clarified the mechanism(s) underlying tiagabine’s action, it is conceivable that the effects described by Zonouzi et al. (<xref ref-type="bibr" rid="B60">2015</xref>) and Liu et al. (<xref ref-type="bibr" rid="B34">2015</xref>) depend on a direct action on GAT-1 expression by microglial cells and oligodendrocytes, which may go some way toward explaining the findings of the two groups.</p>
</sec>
<sec id="s3">
<title>Evidence for a Widespread Cellular Expression of GAT-1</title>
<p>Some years ago, while investigating GAT-1 immunoreactivity in subcortical white matter, we detected GAT-1 cells of different sizes and morphologies (<xref ref-type="fig" rid="F1">Figure 1</xref>). Some were small and round with small processes (<xref ref-type="fig" rid="F1">Figure 1A</xref>), and others were medium-sized, rounded or oval with regular profiles; some medium-sized cells had a pyramidal shape with long and intensely stained processes, whereas other cells were large and elongated. The frequency distribution of their diameter is reported in <xref ref-type="fig" rid="F1">Figure 1B</xref>. The broad difference in the size and morphology of these subcortical white matter cells suggested to us that they might belong to different types. We therefore set up a study to examine them in detail.</p>
<fig id="F1" position="float">
<label>Figure 1</label>
<caption>
<p><bold>(A)</bold> GAT-1 immunoreactivity in the subcortical white matter reveals the presence of numerous cells of small and medium size (arrows) and of different morphology. <bold>(B)</bold> Frequency and <bold>(C)</bold> cumulative frequency distribution of the diameter of GAT-1-positive cells. Bar: 20 μm (modified from Fattorini et al., <xref ref-type="bibr" rid="B20">2017</xref>).</p>
</caption>
<graphic xlink:href="fncel-14-00009-g0001"></graphic>
</fig>
<p>In line with earlier work (Minelli et al., <xref ref-type="bibr" rid="B44">1995</xref>; Conti et al., <xref ref-type="bibr" rid="B10">1998</xref>), electron microscopic (EM) observation demonstrated that GAT-1 was robustly expressed in axon terminals forming symmetric synapses and in astrocytic processes. However, its astrocytic expression was more diffuse than expected and, even more surprisingly, immature and mature oligodendrocytes and microglial cells also expressed the transporter (<xref ref-type="fig" rid="F2">Figure 2</xref>).</p>
<fig id="F2" position="float">
<label>Figure 2</label>
<caption>
<p><bold>(A–D)</bold> Four low-magnification electron microscopic (EM) fields showing GAT-1 immunoreactivity in cerebral neocortex (layers II–III of rat parietal cortex). Colored profiles code for different GAT-1-positive cell types and/or profiles: blue, axon terminals, axon, and neuron; yellow, astrocyte and astrocytic processes; green, oligodendrocyte; red, microglial cell. Framed regions in <bold>(A–D)</bold> are reproduced and enlarged, in the lowest portion of the figure. Bar: 2.5 μm for <bold>(A–D)</bold>; 0.8 and 1 μm for enlarged frames of <bold>(A)</bold> and <bold>(B–D)</bold>, respectively (modified from Melone et al., <xref ref-type="bibr" rid="B42">2015</xref>; Fattorini et al., <xref ref-type="bibr" rid="B20">2017</xref>, <xref ref-type="bibr" rid="B19">2020</xref>).</p>
</caption>
<graphic xlink:href="fncel-14-00009-g0002"></graphic>
</fig>
<sec id="s3-1">
<title>Astrocytes</title>
<p>Recently, quantitative EM analysis, performed in our laboratory, disclosed hitherto unknown features of astrocytic GAT-1 localization in rat cerebral cortex; in particular, we found that: (i) approximately 43% of GAT-1+ profiles in the cortical neuropil are astrocytic processes; (ii) at synaptic loci, GAT-1+ astrocytic processes lie close to the pre- and postsynaptic elements of symmetric as well as asymmetric synapses; and (iii) astrocytic GAT-1 expression at symmetric synapses is not homogeneous, since in ~15% of cases it is associated to GAT-1+ axon terminals and in ~22% of cases it is exclusively localized in astrocytic processes associated to symmetric synapses (i.e., not expressing GAT-1 in axon terminals). The latter fraction of astrocytic GAT-1 increases to up to ~38% in GABAergic synapses targeting distal dendrites and spines, where GAT-1+ axon terminals are less numerous (Melone et al., <xref ref-type="bibr" rid="B41">2014</xref>). Immunogold EM demonstrated that the density of GAT-1 molecules in astrocytic process membranes was ~3.5 times higher than in axon terminals and displayed a continuous distribution from perisynaptic to extrasynaptic regions (respectively within and over 300 nm from the borders of the symmetric synapse specializations), with peaks of concentration at ~950 nm; in contrast, GAT-1 molecules in the membranes of axon terminals showed a preferential perisynaptic localization (Melone et al., <xref ref-type="bibr" rid="B42">2015</xref>).</p>
</sec>
<sec id="s3-2">
<title>Oligodendrocytes</title>
<p>EM analysis revealed GAT-1 immunoreactivity in immature and mature oligodendrocytes both in gray matter and in subcortical white matter. Co-localization studies of GAT-1 and specific oligodendrocyte markers (NG2 and RIP) demonstrated that approximately 12% of GAT-1+ cells in white matter were immature oligodendrocytes and that about 15% were mature oligodendrocytes. Studies of radiolabeled GABA uptake, performed to establish whether GAT-1 localized in oligodendrocytes was functional, demonstrated significant inhibition of Na+-dependent GABA uptake in the presence of tiagabine, indicating that GABA uptake in oligodendrocytes is driven by GAT-1 (Fattorini et al., <xref ref-type="bibr" rid="B20">2017</xref>).</p>
</sec>
<sec id="s3-3">
<title>Microglial Cells</title>
<p>EM analysis also demonstrated GAT-1 immunoreactivity in the soma of microglial cells in subcortical white matter and cortical gray matter as well as in microglial processes, where GAT-1 was localized predominantly in the proximal portion. To quantify GAT-1 protein in microglial cells, we measured the volume of the cells containing the GAT-1 protein signal (in cx3cr1+/gfp animals) and found that it was ~3% in subcortical white matter and ~8% in cortical gray matter. We also established that Na+-dependent GABA uptake was significantly inhibited by NNC-711, a potent GABA uptake inhibitor with high affinity and selectivity for GAT-1 (Borden et al., <xref ref-type="bibr" rid="B3">1994</xref>). In addition, we documented that, like neurons, microglial cells can regulate the membrane expression of GAT-1 in a syntaxin1A-dependent manner (Deken et al., <xref ref-type="bibr" rid="B15">2000</xref>), since syntaxin1A-specific cleavage by botulin toxin C1 (Schiavo et al., <xref ref-type="bibr" rid="B51">1995</xref>; Deken et al., <xref ref-type="bibr" rid="B15">2000</xref>) completely blocks GAT-1-dependent modulation of GABA uptake (Fattorini et al., <xref ref-type="bibr" rid="B19">2020</xref>).</p>
</sec>
</sec>
<sec id="s4" sec-type="discussion">
<title>Discussion</title>
<p>The notion that GAT-1 is not an exclusively “neuronal” transporter appears to be gaining momentum. Indeed, quantitative analysis of GAT-1 in the cerebral cortex, performed in our laboratory, showed that 54% of GAT-1 + profiles were neuronal and that no less than 42% were astrocytic (Melone et al., <xref ref-type="bibr" rid="B42">2015</xref>). More recently, we reported significant GAT-1 expression in oligodendrocytes and microglia (Fattorini et al., <xref ref-type="bibr" rid="B20">2017</xref>, <xref ref-type="bibr" rid="B19">2020</xref>; <xref ref-type="fig" rid="F2">Figure 2</xref>). In this connection, it is worth noting that GAT-3, a putative “glial” transporter (see Minelli et al., <xref ref-type="bibr" rid="B45">1996</xref> for the neocortex), also seems to be expressed in brainstem and cortical neurons, at least in certain experimental conditions (Clark et al., <xref ref-type="bibr" rid="B9">1992</xref>; Melone et al., <xref ref-type="bibr" rid="B43">2003</xref>, <xref ref-type="bibr" rid="B40">2005</xref>, <xref ref-type="bibr" rid="B42">2015</xref>), and that GAT-2, another putative “glial” transporter, is expressed in epithelial cells and, although at a very low level, also in neurons (Conti et al., <xref ref-type="bibr" rid="B13">1999</xref>). It therefore seems that the era of “neuronal” and “glial” GABA transporters has finally come to a close.</p>
<p>The demonstration that all major brain cells express GAT-1 will conceivably contribute to generate a wider framework through which to assess (and indeed reassess) numerous cerebral GABA-mediated phenomena that occur in physiological conditions. This requires tackling first the issue of the physiological role of GAT-1 in oligodendrocytes and microglial cells. Given the well-established involvement of astrocytes, oligodendrocytes, and microglial cells in pathophysiological conditions (Verkhratsky and Butt, <xref ref-type="bibr" rid="B58">2013</xref>), the demonstration of functional GAT-1 in these cells is expected to provide greater insight into the phenomena occurring in the diseased brain and to prompt a reappraisal of earlier findings. Notably, one of the studies that stimulated the present reassessment (Zonouzi et al., <xref ref-type="bibr" rid="B60">2015</xref>) can now be interpreted as showing that the contribution of GAT-1 to the pathophysiology of DWMI may be mediated by oligodendrocytes, and a similar situation may well arise for the ID seen in some forms of epilepsy. Also, the findings reported by Liu et al. (<xref ref-type="bibr" rid="B34">2015</xref>) could simply be interpreted as indicating that GAT-1 expression by microglia may be the direct mechanism by which the transporter contributes to the pathophysiology of Parkinson’s disease.</p>
</sec>
<sec id="s5">
<title>Author Contributions</title>
<p>GF, MM, and FC discussed the project, realized the figures, and wrote the article.</p>
</sec>
<sec id="s6">
<title>Conflict of Interest</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
</body>
<back>
<fn-group>
<fn fn-type="financial-disclosure">
<p><bold>Funding.</bold> This work was supported by Ministero dell’Istruzione, dell’Università e della Ricerca (MIUR; 2015H4K2CR_002) and Università Politecnica delle Marche (PSA2018). We are indebted to the colleagues who collaborated in the original studies and to NC Brecha (Los Angeles, CA, USA) for providing the GAT-1 antibody.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="B1">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bitanihirwe</surname><given-names>B. K. Y.</given-names></name><name><surname>Woo</surname><given-names>T. U. W.</given-names></name></person-group> (<year>2014</year>). <article-title>Transcriptional dysregulation of γ-aminobutyric acid transporter in parvalbumin-containing inhibitory neurons in the prefrontal cortex in schizophrenia</article-title>. <source/>Psychiatry Res.
<volume>220</volume>, <fpage>1155</fpage>–<lpage>1159</lpage>. <pub-id pub-id-type="doi">10.1016/j.psychres.2014.09.016</pub-id><pub-id pub-id-type="pmid">25312391</pub-id></mixed-citation>
</ref>
<ref id="B2">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Borden</surname><given-names>L. A.</given-names></name></person-group> (<year>1996</year>). <article-title>GABA transporter heterogeneity: pharmacology and cellular localization</article-title>. <source/>Neurochem. Int.
<volume>29</volume>, <fpage>335</fpage>–<lpage>356</lpage>. <pub-id pub-id-type="doi">10.1016/0197-0186(95)00158-1</pub-id><pub-id pub-id-type="pmid">8939442</pub-id></mixed-citation>
</ref>
<ref id="B3">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Borden</surname><given-names>L. A.</given-names></name><name><surname>Dhar</surname><given-names>T. G. M.</given-names></name><name><surname>Smith</surname><given-names>K. E.</given-names></name><name><surname>Weinshank</surname><given-names>R. L.</given-names></name><name><surname>Branchek</surname><given-names>T. A.</given-names></name><name><surname>Gluchowski</surname><given-names>C.</given-names></name></person-group> (<year>1994</year>). <article-title>Tiagabine, SK &amp; F 89976-A, CI-966, and NNC-711 are selective for the cloned GABA transporter GAT-1</article-title>. <source/>Eur. J. Pharmacol.
<volume>269</volume>, <fpage>219</fpage>–<lpage>224</lpage>. <pub-id pub-id-type="doi">10.1016/0922-4106(94)90089-2</pub-id><pub-id pub-id-type="pmid">7851497</pub-id></mixed-citation>
</ref>
<ref id="B4">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Braestrup</surname><given-names>C.</given-names></name><name><surname>Nielsen</surname><given-names>E. B.</given-names></name><name><surname>Sonnewald</surname><given-names>U.</given-names></name><name><surname>Knutsen</surname><given-names>L. J. S.</given-names></name><name><surname>Andersen</surname><given-names>K. E.</given-names></name><name><surname>Jansen</surname><given-names>J. A.</given-names></name><etal></etal></person-group>. (<year>1990</year>). <article-title>(R)-N-[4,4-bis(3-methyl-2-thienyl)but-3-en-yl]nipecotic acid binds with high affinity to the brain gamma-aminobutyric acid uptake carrier</article-title>. <source/>J. Neurosci.
<volume>54</volume>, <fpage>639</fpage>–<lpage>647</lpage>. <pub-id pub-id-type="doi">10.1111/j.1471-4159.1990.tb01919.x</pub-id><pub-id pub-id-type="pmid">2299358</pub-id></mixed-citation>
</ref>
<ref id="B5">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bragina</surname><given-names>L.</given-names></name><name><surname>Marchionni</surname><given-names>I.</given-names></name><name><surname>Omrani</surname><given-names>A.</given-names></name><name><surname>Cozzi</surname><given-names>A.</given-names></name><name><surname>Pellegrini-Giampietro</surname><given-names>D. E.</given-names></name><name><surname>Cherubini</surname><given-names>E.</given-names></name><etal></etal></person-group>. (<year>2008</year>). <article-title>GAT-1 regulates both tonic and phasic GABA<sub>A</sub> receptor-mediated inhibition in the cerebral cortex</article-title>. <source/>J. Neurochem.
<volume>105</volume>, <fpage>1781</fpage>–<lpage>1793</lpage>. <pub-id pub-id-type="doi">10.1111/j.1471-4159.2008.05273.x</pub-id><pub-id pub-id-type="pmid">18248614</pub-id></mixed-citation>
</ref>
<ref id="B6">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cai</surname><given-names>K.</given-names></name><name><surname>Wang</surname><given-names>J.</given-names></name><name><surname>Eissman</surname><given-names>J.</given-names></name><name><surname>Wang</surname><given-names>J.</given-names></name><name><surname>Nwosu</surname><given-names>G.</given-names></name><name><surname>Shen</surname><given-names>W.</given-names></name><etal></etal></person-group>. (<year>2019</year>). <article-title>A missense mutation in SLC6A1 associated with Lennox–Gastaut syndrome impairs GABA transporter 1 protein trafficking and function</article-title>. <source/>Exp. Neurol.
<volume>320</volume>:<fpage>112973</fpage>. <pub-id pub-id-type="doi">10.1016/j.expneurol.2019.112973</pub-id><pub-id pub-id-type="pmid">31176687</pub-id></mixed-citation>
</ref>
<ref id="B7">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carvill</surname><given-names>G. L.</given-names></name><name><surname>McMahon</surname><given-names>J. M.</given-names></name><name><surname>Schneider</surname><given-names>A.</given-names></name><name><surname>Zemel</surname><given-names>M.</given-names></name><name><surname>Myers</surname><given-names>C. T.</given-names></name><name><surname>Saykally</surname><given-names>J.</given-names></name><etal></etal></person-group>. (<year>2015</year>). <article-title>Mutations in the GABA transporter SLC6A1 cause epilepsy with myoclonic-atonic seizures</article-title>. <source/>Am. J. Hum. Genet.
<volume>96</volume>, <fpage>808</fpage>–<lpage>815</lpage>. <pub-id pub-id-type="doi">10.1016/j.ajhg.2015.02.016</pub-id><pub-id pub-id-type="pmid">25865495</pub-id></mixed-citation>
</ref>
<ref id="B8">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cherubini</surname><given-names>E.</given-names></name><name><surname>Conti</surname><given-names>F.</given-names></name></person-group> (<year>2001</year>). <article-title>Generating diversity at GABAergic synapses</article-title>. <source/>Trends Neurosci.
<volume>24</volume>, <fpage>155</fpage>–<lpage>162</lpage>. <pub-id pub-id-type="doi">10.1016/s0166-2236(00)01724-0</pub-id><pub-id pub-id-type="pmid">11182455</pub-id></mixed-citation>
</ref>
<ref id="B9">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Clark</surname><given-names>J. A.</given-names></name><name><surname>Deutch</surname><given-names>A. Y.</given-names></name><name><surname>Gallipoli</surname><given-names>P. Z.</given-names></name><name><surname>Amara</surname><given-names>S. G.</given-names></name></person-group> (<year>1992</year>). <article-title>Functional expression and CNS distribution of a β-alanine-sensitive neuronal GABA transporter</article-title>. <source/>Neuron
<volume>9</volume>, <fpage>337</fpage>–<lpage>348</lpage>. <pub-id pub-id-type="doi">10.1016/0896-6273(92)90172-a</pub-id><pub-id pub-id-type="pmid">1497897</pub-id></mixed-citation>
</ref>
<ref id="B10">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Conti</surname><given-names>F.</given-names></name><name><surname>Melone</surname><given-names>M.</given-names></name><name><surname>De Biasi</surname><given-names>S.</given-names></name><name><surname>Minelli</surname><given-names>A.</given-names></name><name><surname>Brecha</surname><given-names>N. C.</given-names></name><name><surname>Ducati</surname><given-names>A.</given-names></name></person-group> (<year>1998</year>). <article-title>Neuronal and glial localization of GAT-1, a high-affinity γ-aminobutyric acid plasma membrane transporter, in human cerebral cortex: with a note on its distribution in monkey cortex</article-title>. <source/>J. Comp. Neurol.
<volume>396</volume>, <fpage>51</fpage>–<lpage>63</lpage>. <pub-id pub-id-type="doi">10.1002/(sici)1096-9861(19980622)396:1&lt;51::aid-cne5&gt;3.0.co;2-h</pub-id><pub-id pub-id-type="pmid">9623887</pub-id></mixed-citation>
</ref>
<ref id="B11">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Conti</surname><given-names>F.</given-names></name><name><surname>Melone</surname><given-names>M.</given-names></name><name><surname>Fattorini</surname><given-names>G.</given-names></name><name><surname>Bragina</surname><given-names>L.</given-names></name><name><surname>Ciappelloni</surname><given-names>S.</given-names></name></person-group> (<year>2011</year>). <article-title>A role for GAT-1 in presynaptic GABA homeostasis?</article-title>
<source/>Front. Cell. Neurosci.
<volume>5</volume>:<fpage>2</fpage>. <pub-id pub-id-type="doi">10.3389/fncel.2011.00002</pub-id><pub-id pub-id-type="pmid">21503156</pub-id></mixed-citation>
</ref>
<ref id="B12">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Conti</surname><given-names>F.</given-names></name><name><surname>Minelli</surname><given-names>A.</given-names></name><name><surname>Melone</surname><given-names>M.</given-names></name></person-group> (<year>2004</year>). <article-title>GABA transporters in the mammalian cerebral cortex: localization, development and pathological implications</article-title>. <source/>Brain Res. Rev.
<volume>45</volume>, <fpage>196</fpage>–<lpage>212</lpage>. <pub-id pub-id-type="doi">10.1016/j.brainresrev.2004.03.003</pub-id><pub-id pub-id-type="pmid">15210304</pub-id></mixed-citation>
</ref>
<ref id="B13">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Conti</surname><given-names>F.</given-names></name><name><surname>Zuccarello</surname><given-names>L. V.</given-names></name><name><surname>Barbaresi</surname><given-names>P.</given-names></name><name><surname>Minelli</surname><given-names>A.</given-names></name><name><surname>Brecha</surname><given-names>N. C.</given-names></name><name><surname>Melone</surname><given-names>M.</given-names></name></person-group> (<year>1999</year>). <article-title>Neuronal, glial, and epithelial localization of γ-aminobutyric acid transporter 2, a high-affinity γ-aminobutyric acid plasma membrane transporter, in the cerebral cortex and neighboring structures</article-title>. <source/>J. Comp. Neurol.
<volume>409</volume>, <fpage>482</fpage>–<lpage>494</lpage>. <pub-id pub-id-type="doi">10.1002/(SICI)1096-9861(19990705)409:3&lt;482::AID-CNE11&gt;3.0.CO;2-O</pub-id><pub-id pub-id-type="pmid">10379832</pub-id></mixed-citation>
</ref>
<ref id="B14">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cope</surname><given-names>D. W.</given-names></name><name><surname>Di Giovanni</surname><given-names>G.</given-names></name><name><surname>Fyson</surname><given-names>S. J.</given-names></name><name><surname>Orbán</surname><given-names>G.</given-names></name><name><surname>Errington</surname><given-names>A. C.</given-names></name><name><surname>Lrincz</surname><given-names>M. L.</given-names></name><etal></etal></person-group>. (<year>2009</year>). <article-title>Enhanced tonic GABA<sub>A</sub> inhibition in typical absence epilepsy</article-title>. <source/>Nat. Med.
<volume>15</volume>, <fpage>1392</fpage>–<lpage>1398</lpage>. <pub-id pub-id-type="doi">10.1038/nm.2058</pub-id><pub-id pub-id-type="pmid">19966779</pub-id></mixed-citation>
</ref>
<ref id="B15">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Deken</surname><given-names>S. L.</given-names></name><name><surname>Beckman</surname><given-names>M. L.</given-names></name><name><surname>Boos</surname><given-names>L.</given-names></name><name><surname>Quick</surname><given-names>M. W.</given-names></name></person-group> (<year>2000</year>). <article-title>Transport rates of GABA transporters: regulation by the N-terminal domain and syntaxin 1A</article-title>. <source/>Nat. Neurosci.
<volume>3</volume>, <fpage>998</fpage>–<lpage>1003</lpage>. <pub-id pub-id-type="doi">10.1038/79939</pub-id><pub-id pub-id-type="pmid">11017172</pub-id></mixed-citation>
</ref>
<ref id="B16">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Di Marco</surname><given-names>B.</given-names></name><name><surname>M. Bonaccorso</surname><given-names>C.</given-names></name><name><surname>Aloisi</surname><given-names>E.</given-names></name><name><surname>D’Antoni</surname><given-names>S.</given-names></name><name><surname>V. Catania</surname><given-names>M.</given-names></name></person-group> (<year>2016</year>). <article-title>Neuro-inflammatory mechanisms in developmental disorders associated with intellectual disability and autism spectrum disorder: a neuro-immune perspective</article-title>. <source/>CNS Neurol. Disord. Drug Targets
<volume>15</volume>, <fpage>448</fpage>–<lpage>463</lpage>. <pub-id pub-id-type="doi">10.2174/1871527315666160321105039</pub-id><pub-id pub-id-type="pmid">26996174</pub-id></mixed-citation>
</ref>
<ref id="B17">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dikow</surname><given-names>N.</given-names></name><name><surname>Maas</surname><given-names>B.</given-names></name><name><surname>Karch</surname><given-names>S.</given-names></name><name><surname>Granzow</surname><given-names>M.</given-names></name><name><surname>Janssen</surname><given-names>J. W. G.</given-names></name><name><surname>Jauch</surname><given-names>A.</given-names></name><etal></etal></person-group>. (<year>2014</year>). <article-title>3p25.3 microdeletion of GABA transporters SLC6A1 and SLC6A11 results in intellectual disability, epilepsy and stereotypic behavior</article-title>. <source/>Am. J. Med. Genet. A
<volume>164A</volume>, <fpage>3061</fpage>–<lpage>3068</lpage>. <pub-id pub-id-type="doi">10.1002/ajmg.a.36761</pub-id><pub-id pub-id-type="pmid">25256099</pub-id></mixed-citation>
</ref>
<ref id="B18">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dodrill</surname><given-names>C. B.</given-names></name><name><surname>Arnett</surname><given-names>J. L.</given-names></name><name><surname>Shu</surname><given-names>V.</given-names></name><name><surname>Pixton</surname><given-names>G. C.</given-names></name><name><surname>Lenz</surname><given-names>G. T.</given-names></name><name><surname>Sommerville</surname><given-names>K. W.</given-names></name></person-group> (<year>1998</year>). <article-title>Effects of tiagabine monotherapy on abilities, adjustment, and mood</article-title>. <source/>Epilepsia
<volume>39</volume>, <fpage>33</fpage>–<lpage>42</lpage>. <pub-id pub-id-type="doi">10.1111/j.1528-1157.1998.tb01271.x</pub-id><pub-id pub-id-type="pmid">9578010</pub-id></mixed-citation>
</ref>
<ref id="B19">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fattorini</surname><given-names>G.</given-names></name><name><surname>Catalano</surname><given-names>M.</given-names></name><name><surname>Melone</surname><given-names>M.</given-names></name><name><surname>Serpe</surname><given-names>C.</given-names></name><name><surname>Bassi</surname><given-names>S.</given-names></name><name><surname>Limatola</surname><given-names>C.</given-names></name><etal></etal></person-group>. (<year>2020</year>). <article-title>Microglial expression of GAT-1 in the cerebral cortex</article-title>. <source/>Glia
<volume>68</volume>, <fpage>646</fpage>–<lpage>655</lpage>. <pub-id pub-id-type="doi">10.1002/glia.23745</pub-id><pub-id pub-id-type="pmid">31692106</pub-id></mixed-citation>
</ref>
<ref id="B20">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fattorini</surname><given-names>G.</given-names></name><name><surname>Melone</surname><given-names>M.</given-names></name><name><surname>Sánchez-Gómez</surname><given-names>M. V.</given-names></name><name><surname>Arellano</surname><given-names>R. O.</given-names></name><name><surname>Bassi</surname><given-names>S.</given-names></name><name><surname>Matute</surname><given-names>C.</given-names></name><etal></etal></person-group>. (<year>2017</year>). <article-title>GAT-1 mediated GABA uptake in rat oligodendrocytes</article-title>. <source/>Glia
<volume>65</volume>, <fpage>514</fpage>–<lpage>522</lpage>. <pub-id pub-id-type="doi">10.1002/glia.23108</pub-id><pub-id pub-id-type="pmid">28071826</pub-id></mixed-citation>
</ref>
<ref id="B21">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Froestl</surname><given-names>W.</given-names></name></person-group> (<year>2011</year>). <article-title>An historical perspective on GABAergic drugs</article-title>. <source/>Future Med. Chem.
<volume>3</volume>, <fpage>163</fpage>–<lpage>175</lpage>. <pub-id pub-id-type="doi">10.4155/fmc.10.285</pub-id><pub-id pub-id-type="pmid">21428811</pub-id></mixed-citation>
</ref>
<ref id="B22">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fuhrer</surname><given-names>T. E.</given-names></name><name><surname>Palpagama</surname><given-names>T. H.</given-names></name><name><surname>Waldvogel</surname><given-names>H. J.</given-names></name><name><surname>Synek</surname><given-names>B. J. L.</given-names></name><name><surname>Turner</surname><given-names>C.</given-names></name><name><surname>Faull</surname><given-names>R. L.</given-names></name><etal></etal></person-group>. (<year>2017</year>). <article-title>Impaired expression of GABA transporters in the human Alzheimer’s disease hippocampus, subiculum, entorhinal cortex and superior temporal gyrus</article-title>. <source/>Neuroscience
<volume>351</volume>, <fpage>108</fpage>–<lpage>118</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuroscience.2017.03.041</pub-id><pub-id pub-id-type="pmid">28385633</pub-id></mixed-citation>
</ref>
<ref id="B23">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gong</surname><given-names>X.</given-names></name><name><surname>Shao</surname><given-names>Y.</given-names></name><name><surname>Li</surname><given-names>B.</given-names></name><name><surname>Chen</surname><given-names>L.</given-names></name><name><surname>Wang</surname><given-names>C.</given-names></name><name><surname>Chen</surname><given-names>Y.</given-names></name></person-group> (<year>2015</year>). <article-title>γ-aminobutyric acid transporter-1 is involved in anxiety-like behaviors and cognitive function in knockout mice</article-title>. <source/>Exp. Ther. Med.
<volume>10</volume>, <fpage>653</fpage>–<lpage>658</lpage>. <pub-id pub-id-type="doi">10.3892/etm.2015.2577</pub-id><pub-id pub-id-type="pmid">26622370</pub-id></mixed-citation>
</ref>
<ref id="B24">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guastella</surname><given-names>J.</given-names></name><name><surname>Nelson</surname><given-names>N.</given-names></name><name><surname>Nelson</surname><given-names>H.</given-names></name><name><surname>Czyzyk</surname><given-names>L.</given-names></name><name><surname>Keynan</surname><given-names>S.</given-names></name><name><surname>Miedel</surname><given-names>M. C.</given-names></name><etal></etal></person-group>. (<year>1990</year>). <article-title>Cloning and expression of a rat brain GABA transporter</article-title>. <source/>Science
<volume>249</volume>, <fpage>1303</fpage>–<lpage>1306</lpage>. <pub-id pub-id-type="doi">10.1126/science.1975955</pub-id><pub-id pub-id-type="pmid">1975955</pub-id></mixed-citation>
</ref>
<ref id="B25">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Inaba</surname><given-names>T.</given-names></name><name><surname>Miyamoto</surname><given-names>N.</given-names></name><name><surname>Hira</surname><given-names>K.</given-names></name><name><surname>Ueno</surname><given-names>Y.</given-names></name><name><surname>Yamashiro</surname><given-names>K.</given-names></name><name><surname>Watanabe</surname><given-names>M.</given-names></name><etal></etal></person-group>. (<year>2019</year>). <article-title>Protective role of levetiracetam against cognitive impairment and brain white matter damage in mouse prolonged cerebral hypoperfusion</article-title>. <source/>Neuroscience
<volume>414</volume>, <fpage>255</fpage>–<lpage>264</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuroscience.2019.07.015</pub-id><pub-id pub-id-type="pmid">31302262</pub-id></mixed-citation>
</ref>
<ref id="B26">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Iwase</surname><given-names>S.</given-names></name><name><surname>Bérubé</surname><given-names>N. G.</given-names></name><name><surname>Zhou</surname><given-names>Z.</given-names></name><name><surname>Kasri</surname><given-names>N. N.</given-names></name><name><surname>Battaglioli</surname><given-names>E.</given-names></name><name><surname>Scandaglia</surname><given-names>M.</given-names></name><etal></etal></person-group>. (<year>2017</year>). <article-title>Epigenetic etiology of intellectual disability</article-title>. <source/>J. Neurosci.
<volume>37</volume>, <fpage>10773</fpage>–<lpage>10782</lpage>. <pub-id pub-id-type="doi">10.1523/jneurosci.1840-17.2017</pub-id><pub-id pub-id-type="pmid">29118205</pub-id></mixed-citation>
</ref>
<ref id="B27">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jasmin</surname><given-names>L.</given-names></name><name><surname>Wu</surname><given-names>M. V.</given-names></name><name><surname>Ohara</surname><given-names>P. T.</given-names></name></person-group> (<year>2004</year>). <article-title>GABA puts a stop to pain</article-title>. <source/>Curr. Drug Targets CNS Neurol. Disord.
<volume>3</volume>, <fpage>487</fpage>–<lpage>505</lpage>. <pub-id pub-id-type="doi">10.2174/1568007043336716</pub-id><pub-id pub-id-type="pmid">15578966</pub-id></mixed-citation>
</ref>
<ref id="B28">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Johannesen</surname><given-names>K. M.</given-names></name><name><surname>Gardella</surname><given-names>E.</given-names></name><name><surname>Linnankivi</surname><given-names>T.</given-names></name><name><surname>Courage</surname><given-names>C.</given-names></name><name><surname>de Saint Martin</surname><given-names>A.</given-names></name><name><surname>Lehesjoki</surname><given-names>A.-E.</given-names></name><etal></etal></person-group>. (<year>2018</year>). <article-title>Defining the phenotypic spectrum of SLC6A1 mutations</article-title>. <source/>Epilepsia
<volume>59</volume>, <fpage>389</fpage>–<lpage>402</lpage>. <pub-id pub-id-type="doi">10.1111/epi.13986</pub-id><pub-id pub-id-type="pmid">29315614</pub-id></mixed-citation>
</ref>
<ref id="B29">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kanner</surname><given-names>B. I.</given-names></name></person-group> (<year>1978</year>). <article-title>Active transport of γ-aminobutyricacid by membrane vesicles isolated from rat brain</article-title>. <source/>Biochemistry
<volume>17</volume>, <fpage>1207</fpage>–<lpage>1211</lpage>. <pub-id pub-id-type="doi">10.1021/bi00600a011</pub-id><pub-id pub-id-type="pmid">656383</pub-id></mixed-citation>
</ref>
<ref id="B30">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Keynan</surname><given-names>S.</given-names></name><name><surname>Suh</surname><given-names>Y. J.</given-names></name><name><surname>Kanner</surname><given-names>B. I.</given-names></name><name><surname>Rudnick</surname><given-names>G.</given-names></name></person-group> (<year>1992</year>). <article-title>Expression of a cloned γ-aminobutyric acid transporter in mammalian cells</article-title>. <source/>Biochemistry
<volume>31</volume>, <fpage>1974</fpage>–<lpage>1979</lpage>. <pub-id pub-id-type="doi">10.1021/bi00122a011</pub-id><pub-id pub-id-type="pmid">1536839</pub-id></mixed-citation>
</ref>
<ref id="B31">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kinjo</surname><given-names>A.</given-names></name><name><surname>Koito</surname><given-names>T.</given-names></name><name><surname>Kawaguchi</surname><given-names>S.</given-names></name><name><surname>Inoue</surname><given-names>K.</given-names></name></person-group> (<year>2013</year>). <article-title>Evolutionary history of the GABA transporter (GAT) group revealed by marine invertebrate GAT-1</article-title>. <source/>PLoS One
<volume>8</volume>:<fpage>e82410</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0082410</pub-id><pub-id pub-id-type="pmid">24312660</pub-id></mixed-citation>
</ref>
<ref id="B32">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lai</surname><given-names>C. T.</given-names></name><name><surname>Tanay</surname><given-names>V. A. M. I.</given-names></name><name><surname>Charrois</surname><given-names>G. J. R.</given-names></name><name><surname>Baker</surname><given-names>G. B.</given-names></name><name><surname>Bateson</surname><given-names>A. N.</given-names></name></person-group> (<year>1998</year>). <article-title>Effects of phenelzine and imipramine on the steady-state levels of mRNAs that encode glutamic acid decarboxylase (GAD67 and GAD65), the GABA transporter GAT-1 and GABA transaminase in rat cortex</article-title>. <source/>Naunyn. Schmiedebergs Arch. Pharmacol.
<volume>357</volume>, <fpage>32</fpage>–<lpage>38</lpage>. <pub-id pub-id-type="doi">10.1007/pl00005135</pub-id><pub-id pub-id-type="pmid">9459570</pub-id></mixed-citation>
</ref>
<ref id="B33">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lewis</surname><given-names>D. A.</given-names></name><name><surname>Gonzalez-Burgos</surname><given-names>G.</given-names></name></person-group> (<year>2006</year>). <article-title>Pathophysiologically based treatment interventions in schizophrenia</article-title>. <source/>Nat. Med.
<volume>12</volume>, <fpage>1016</fpage>–<lpage>1022</lpage>. <pub-id pub-id-type="doi">10.1038/nm1478</pub-id><pub-id pub-id-type="pmid">16960576</pub-id></mixed-citation>
</ref>
<ref id="B34">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>J.</given-names></name><name><surname>Huang</surname><given-names>D.</given-names></name><name><surname>Xu</surname><given-names>J.</given-names></name><name><surname>Tong</surname><given-names>J.</given-names></name><name><surname>Wang</surname><given-names>Z.</given-names></name><name><surname>Huang</surname><given-names>L.</given-names></name><etal></etal></person-group>. (<year>2015</year>). <article-title>Tiagabine protects dopaminergic neurons against neurotoxins by inhibiting microglial activation</article-title>. <source/>Sci. Rep.
<volume>5</volume>:<fpage>15720</fpage>. <pub-id pub-id-type="doi">10.1038/srep15720</pub-id><pub-id pub-id-type="pmid">26499517</pub-id></mixed-citation>
</ref>
<ref id="B35">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>Q. R.</given-names></name><name><surname>López-Corcuera</surname><given-names>B.</given-names></name><name><surname>Mandiyan</surname><given-names>S.</given-names></name><name><surname>Nelson</surname><given-names>H.</given-names></name><name><surname>Nelson</surname><given-names>N.</given-names></name></person-group> (<year>1993</year>). <article-title>Molecular characterization of four pharmacologically distinct γ-aminobutyric acid transporters in mouse brain</article-title>. <source/>J. Biol. Chem.
<volume>268</volume>, <fpage>2106</fpage>–<lpage>2112</lpage>. <pub-id pub-id-type="pmid">8420981</pub-id></mixed-citation>
</ref>
<ref id="B36">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lynch</surname><given-names>B. A.</given-names></name><name><surname>Lambeng</surname><given-names>N.</given-names></name><name><surname>Nocka</surname><given-names>K.</given-names></name><name><surname>Kensel-Hammes</surname><given-names>P.</given-names></name><name><surname>Bajjalieh</surname><given-names>S. M.</given-names></name><name><surname>Matagne</surname><given-names>A.</given-names></name><etal></etal></person-group>. (<year>2004</year>). <article-title>The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam</article-title>. <source/>Proc. Natl. Acad. Sci. U S A
<volume>101</volume>, <fpage>9861</fpage>–<lpage>9866</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.0308208101</pub-id><pub-id pub-id-type="pmid">15210974</pub-id></mixed-citation>
</ref>
<ref id="B37">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maglorius Renkilaraj</surname><given-names>M. R. L.</given-names></name><name><surname>Baudouin</surname><given-names>L.</given-names></name><name><surname>Wells</surname><given-names>C. M.</given-names></name><name><surname>Doulazmi</surname><given-names>M.</given-names></name><name><surname>Wehrlé</surname><given-names>R.</given-names></name><name><surname>Cannaya</surname><given-names>V.</given-names></name><etal></etal></person-group>. (<year>2017</year>). <article-title>The intellectual disability protein PAK3 regulates oligodendrocyte precursor cell differentiation</article-title>. <source/>Neurobiol. Dis.
<volume>98</volume>, <fpage>137</fpage>–<lpage>148</lpage>. <pub-id pub-id-type="doi">10.1016/j.nbd.2016.12.004</pub-id><pub-id pub-id-type="pmid">27940202</pub-id></mixed-citation>
</ref>
<ref id="B38">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marcotulli</surname><given-names>D.</given-names></name><name><surname>Fattorini</surname><given-names>G.</given-names></name><name><surname>Bragina</surname><given-names>L.</given-names></name><name><surname>Perugini</surname><given-names>J.</given-names></name><name><surname>Conti</surname><given-names>F.</given-names></name></person-group> (<year>2017</year>). <article-title>Levetiracetam affects differentially presynaptic proteins in rat cerebral cortex</article-title>. <source/>Front. Cell. Neurosci.
<volume>11</volume>:<fpage>389</fpage>. <pub-id pub-id-type="doi">10.3389/fncel.2017.00389</pub-id><pub-id pub-id-type="pmid">29311825</pub-id></mixed-citation>
</ref>
<ref id="B39">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mattison</surname><given-names>K. A.</given-names></name><name><surname>Butler</surname><given-names>K. M.</given-names></name><name><surname>Inglis</surname><given-names>G. A. S.</given-names></name><name><surname>Dayan</surname><given-names>O.</given-names></name><name><surname>Boussidan</surname><given-names>H.</given-names></name><name><surname>Bhambhani</surname><given-names>V.</given-names></name><etal></etal></person-group>. (<year>2018</year>). <article-title>SLC6A1 variants identified in epilepsy patients reduce γ-aminobutyric acid transport</article-title>. <source/>Epilepsia
<volume>59</volume>, <fpage>e135</fpage>–<lpage>e141</lpage>. <pub-id pub-id-type="doi">10.1111/epi.14531</pub-id><pub-id pub-id-type="pmid">30132828</pub-id></mixed-citation>
</ref>
<ref id="B40">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Melone</surname><given-names>M.</given-names></name><name><surname>Barbaresi</surname><given-names>P.</given-names></name><name><surname>Fattorini</surname><given-names>G.</given-names></name><name><surname>Conti</surname><given-names>F.</given-names></name></person-group> (<year>2005</year>). <article-title>Neuronal localization of the GABA transporter GAT-3 in human cerebral cortex: a procedural artifact?</article-title>
<source/>J. Chem. Neuroanat.
<volume>30</volume>, <fpage>45</fpage>–<lpage>54</lpage>. <pub-id pub-id-type="doi">10.1016/j.jchemneu.2005.04.002</pub-id><pub-id pub-id-type="pmid">15923108</pub-id></mixed-citation>
</ref>
<ref id="B41">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Melone</surname><given-names>M.</given-names></name><name><surname>Ciappelloni</surname><given-names>S.</given-names></name><name><surname>Conti</surname><given-names>F.</given-names></name></person-group> (<year>2014</year>). <article-title>Plasma membrane transporters GAT-1 and GAT-3 contribute to heterogeneity of GABAergic synapses in neocortex</article-title>. <source/>Front. Neuroanat.
<volume>8</volume>:<fpage>72</fpage>. <pub-id pub-id-type="doi">10.3389/fnana.2014.00072</pub-id><pub-id pub-id-type="pmid">25120439</pub-id></mixed-citation>
</ref>
<ref id="B42">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Melone</surname><given-names>M.</given-names></name><name><surname>Ciappelloni</surname><given-names>S.</given-names></name><name><surname>Conti</surname><given-names>F.</given-names></name></person-group> (<year>2015</year>). <article-title>A quantitative analysis of cellular and synaptic localization of GAT-1 and GAT-3 in rat neocortex</article-title>. <source/>Brain Struct. Funct.
<volume>220</volume>, <fpage>885</fpage>–<lpage>897</lpage>. <pub-id pub-id-type="doi">10.1007/s00429-013-0690-8</pub-id><pub-id pub-id-type="pmid">24368619</pub-id></mixed-citation>
</ref>
<ref id="B43">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Melone</surname><given-names>M.</given-names></name><name><surname>Cozzi</surname><given-names>A.</given-names></name><name><surname>Pellegrini-Giampietro</surname><given-names>D. E.</given-names></name><name><surname>Conti</surname><given-names>F.</given-names></name></person-group> (<year>2003</year>). <article-title>Transient focal ischemia triggers neuronal expression of GAT-3 in the rat perilesional cortex</article-title>. <source/>Neurobiol. Dis.
<volume>14</volume>, <fpage>120</fpage>–<lpage>132</lpage>. <pub-id pub-id-type="doi">10.1016/s0969-9961(03)00042-1</pub-id><pub-id pub-id-type="pmid">13678673</pub-id></mixed-citation>
</ref>
<ref id="B44">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Minelli</surname><given-names>A.</given-names></name><name><surname>Brecha</surname><given-names>N. C.</given-names></name><name><surname>Karschin</surname><given-names>C.</given-names></name><name><surname>DeBiasi</surname><given-names>S.</given-names></name><name><surname>Conti</surname><given-names>F.</given-names></name></person-group> (<year>1995</year>). <article-title>GAT-1, a high-affinity GABA plasma membrane transporter, is localized to neurons and astroglia in the cerebral cortex</article-title>. <source/>J. Neurosci.
<volume>15</volume>, <fpage>7734</fpage>–<lpage>7746</lpage>. <pub-id pub-id-type="doi">10.1523/jneurosci.15-11-07734.1995</pub-id><pub-id pub-id-type="pmid">7472524</pub-id></mixed-citation>
</ref>
<ref id="B45">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Minelli</surname><given-names>A.</given-names></name><name><surname>DeBiasi</surname><given-names>S.</given-names></name><name><surname>Brecha</surname><given-names>N. C.</given-names></name><name><surname>Zuccarello</surname><given-names>L. V.</given-names></name><name><surname>Conti</surname><given-names>F.</given-names></name></person-group> (<year>1996</year>). <article-title>GAT-3, a high-affinity GABA plasma membrane transporter, is localized to astrocytic processes and it is not confined to the vicinity of GABAergic synapses in the cerebral cortex</article-title>. <source/>J. Neurosci.
<volume>16</volume>, <fpage>6255</fpage>–<lpage>6264</lpage>. <pub-id pub-id-type="doi">10.1523/jneurosci.16-19-06255.1996</pub-id><pub-id pub-id-type="pmid">8815906</pub-id></mixed-citation>
</ref>
<ref id="B46">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nägga</surname><given-names>K.</given-names></name><name><surname>Bogdanovic</surname><given-names>N.</given-names></name><name><surname>Marcusson</surname><given-names>J.</given-names></name></person-group> (<year>1999</year>). <article-title>GABA transporters (GAT-1) in Alzheimer’s disease</article-title>. <source/>J. Neural Transm.
<volume>106</volume>, <fpage>1141</fpage>–<lpage>1149</lpage>. <pub-id pub-id-type="doi">10.1007/s007020050230</pub-id><pub-id pub-id-type="pmid">10651110</pub-id></mixed-citation>
</ref>
<ref id="B47">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pierri</surname><given-names>J. N.</given-names></name><name><surname>Chaudry</surname><given-names>A. S.</given-names></name><name><surname>Woo</surname><given-names>T. U. W.</given-names></name><name><surname>Lewis</surname><given-names>D. A.</given-names></name></person-group> (<year>1999</year>). <article-title>Alterations in chandelier neuron axon terminals in the prefrontal cortex of schizophrenic subjects</article-title>. <source/>Am. J. Psychiatry
<volume>156</volume>, <fpage>1709</fpage>–<lpage>1719</lpage>. <pub-id pub-id-type="doi">10.1176/ajp.156.11.1709</pub-id><pub-id pub-id-type="pmid">10553733</pub-id></mixed-citation>
</ref>
<ref id="B48">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Posar</surname><given-names>A.</given-names></name><name><surname>Visconti</surname><given-names>P.</given-names></name></person-group> (<year>2019</year>). <article-title>Mild phenotype associated with <italic>SLC6A1</italic> gene mutation: a case report with literature review</article-title>. <source/>J. Pediatr. Neurosci.
<volume>14</volume>, <fpage>100</fpage>–<lpage>102</lpage>. <pub-id pub-id-type="doi">10.4103/jpn.jpn_2_19</pub-id><pub-id pub-id-type="pmid">31516630</pub-id></mixed-citation>
</ref>
<ref id="B49">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sałat</surname><given-names>K.</given-names></name><name><surname>Podkowa</surname><given-names>A.</given-names></name><name><surname>Kowalczyk</surname><given-names>P.</given-names></name><name><surname>Kulig</surname><given-names>K.</given-names></name><name><surname>Dziubina</surname><given-names>A.</given-names></name><name><surname>Filipek</surname><given-names>B.</given-names></name><etal></etal></person-group>. (<year>2015</year>). <article-title>Anticonvulsant active inhibitor of GABA transporter subtype 1, tiagabine, with activity in mouse models of anxiety, pain and depression</article-title>. <source/>Pharmacol. Rep.
<volume>67</volume>, <fpage>465</fpage>–<lpage>472</lpage>. <pub-id pub-id-type="doi">10.1016/j.pharep.2014.11.003</pub-id><pub-id pub-id-type="pmid">25933955</pub-id></mixed-citation>
</ref>
<ref id="B50">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Savtchenko</surname><given-names>L.</given-names></name><name><surname>Megalogeni</surname><given-names>M.</given-names></name><name><surname>Rusakov</surname><given-names>D. A.</given-names></name><name><surname>Walker</surname><given-names>M. C.</given-names></name><name><surname>Pavlov</surname><given-names>I.</given-names></name></person-group> (<year>2015</year>). <article-title>Synaptic GABA release prevents GABA transporter type-1 reversal during excessive network activity</article-title>. <source/>Nat. Commun.
<volume>6</volume>:<fpage>6597</fpage>. <pub-id pub-id-type="doi">10.1038/ncomms7597</pub-id><pub-id pub-id-type="pmid">25798861</pub-id></mixed-citation>
</ref>
<ref id="B51">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schiavo</surname><given-names>G.</given-names></name><name><surname>Shone</surname><given-names>C. C.</given-names></name><name><surname>Bennett</surname><given-names>M. K.</given-names></name><name><surname>Scheller</surname><given-names>R. H.</given-names></name><name><surname>Montecucco</surname><given-names>C.</given-names></name></person-group> (<year>1995</year>). <article-title>Botulinum neurotoxin type C cleaves a single Lys-Ala bond within the carboxyl-terminal region of syntaxins</article-title>. <source/>J. Biol. Chem.
<volume>270</volume>, <fpage>10566</fpage>–<lpage>10570</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.270.18.10566</pub-id><pub-id pub-id-type="pmid">7737992</pub-id></mixed-citation>
</ref>
<ref id="B52">
<mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Schousboe</surname><given-names>A.</given-names></name><name><surname>White</surname><given-names>H. S.</given-names></name></person-group> (<year>2009</year>). “<article-title>Glial modulation of excitability <italic>via</italic> glutamate and GABA transporters</article-title>,” in <source/>Encyclopedia of Basic Epilepsy Research, ed. <person-group person-group-type="editor"><name><surname>Scheartzkroin</surname><given-names>P. A.</given-names></name></person-group> (<publisher-loc>Oxford</publisher-loc>: <publisher-name>Academic Press</publisher-name>), <fpage>397</fpage>–<lpage>401</lpage>.</mixed-citation>
</ref>
<ref id="B53">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scimemi</surname><given-names>A.</given-names></name></person-group> (<year>2014</year>). <article-title>Structure, function, and plasticity of GABA transporters</article-title>. <source/>Front. Cell. Neurosci.
<volume>8</volume>:<fpage>161</fpage>. <pub-id pub-id-type="doi">10.3389/fncel.2014.00161</pub-id><pub-id pub-id-type="pmid">24987330</pub-id></mixed-citation>
</ref>
<ref id="B54">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shi</surname><given-names>J.</given-names></name><name><surname>Cai</surname><given-names>Y.</given-names></name><name><surname>Liu</surname><given-names>G.</given-names></name><name><surname>Gong</surname><given-names>N.</given-names></name><name><surname>Liu</surname><given-names>Z.</given-names></name><name><surname>Xu</surname><given-names>T.</given-names></name><etal></etal></person-group>. (<year>2012</year>). <article-title>Enhanced learning and memory in GAT1 heterozygous mice</article-title>. <source/>Acta Biochim. Biophys. Sin.
<volume>44</volume>, <fpage>359</fpage>–<lpage>366</lpage>. <pub-id pub-id-type="doi">10.1093/abbs/gms005</pub-id><pub-id pub-id-type="pmid">22318715</pub-id></mixed-citation>
</ref>
<ref id="B55">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sundman-Eriksson</surname><given-names>I.</given-names></name><name><surname>Allard</surname><given-names>P.</given-names></name></person-group> (<year>2002</year>). <article-title>[<sup>3</sup>H]Tiagabine binding to GABA transporter-1 (GAT-1) in suicidal depression</article-title>. <source/>J. Affect. Disord.
<volume>71</volume>, <fpage>29</fpage>–<lpage>33</lpage>. <pub-id pub-id-type="doi">10.1016/s0165-0327(01)00349-4</pub-id><pub-id pub-id-type="pmid">12167498</pub-id></mixed-citation>
</ref>
<ref id="B56">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Suzdak</surname><given-names>P. D.</given-names></name><name><surname>Jansen</surname><given-names>J. A.</given-names></name></person-group> (<year>1995</year>). <article-title>A review of the preclinical pharmacology of tiagabine: a potent and selective anticonvulsant GABA uptake inhibitor</article-title>. <source/>Epilepsia
<volume>36</volume>, <fpage>612</fpage>–<lpage>626</lpage>. <pub-id pub-id-type="doi">10.1111/j.1528-1157.1995.tb02576.x</pub-id><pub-id pub-id-type="pmid">7555976</pub-id></mixed-citation>
</ref>
<ref id="B57">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ueda</surname><given-names>Y.</given-names></name><name><surname>Doi</surname><given-names>T.</given-names></name><name><surname>Nagatomo</surname><given-names>K.</given-names></name><name><surname>Tokumaru</surname><given-names>J.</given-names></name><name><surname>Takaki</surname><given-names>M.</given-names></name><name><surname>Willmore</surname><given-names>L. J.</given-names></name></person-group> (<year>2007</year>). <article-title>Effect of levetiracetam on molecular regulation of hippocampal glutamate and GABA transporters in rats with chronic seizures induced by amygdalar FeCl3 injection</article-title>. <source/>Brain Res.
<volume>1151</volume>, <fpage>55</fpage>–<lpage>61</lpage>. <pub-id pub-id-type="doi">10.1016/j.brainres.2007.03.021</pub-id><pub-id pub-id-type="pmid">17408599</pub-id></mixed-citation>
</ref>
<ref id="B58">
<mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Verkhratsky</surname><given-names>A.</given-names></name><name><surname>Butt</surname><given-names>A.</given-names></name></person-group> (<year>2013</year>). <source/>Glial Physiology and Pathophysiology.
<publisher-loc>Oxford</publisher-loc>: <publisher-name>John Wiley &amp; Sons</publisher-name>.</mixed-citation>
</ref>
<ref id="B59">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zafar</surname><given-names>S.</given-names></name><name><surname>Jabeen</surname><given-names>I.</given-names></name></person-group> (<year>2018</year>). <article-title>Structure, function and modulation of γ-aminobutyric, acid transporter 1 (GAT1) in neurological disorders: a pharmacoinformatic prospective</article-title>. <source/>Front. Chem.
<volume>6</volume>:<fpage>397</fpage>. <pub-id pub-id-type="doi">10.3389/fchem.2018.00397</pub-id><pub-id pub-id-type="pmid">30255012</pub-id></mixed-citation>
</ref>
<ref id="B60">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zonouzi</surname><given-names>M.</given-names></name><name><surname>Scafidi</surname><given-names>J.</given-names></name><name><surname>Li</surname><given-names>P.</given-names></name><name><surname>McEllin</surname><given-names>B.</given-names></name><name><surname>Edwards</surname><given-names>J.</given-names></name><name><surname>Dupree</surname><given-names>J. L.</given-names></name><etal></etal></person-group>. (<year>2015</year>). <article-title>GABAergic regulation of cerebellar NG2 cell development is altered in perinatal white matter injury</article-title>. <source/>Nat. Neurosci.
<volume>18</volume>, <fpage>674</fpage>–<lpage>682</lpage>. <pub-id pub-id-type="doi">10.1038/nn.3990</pub-id><pub-id pub-id-type="pmid">25821912</pub-id></mixed-citation>
</ref>
</ref-list>
</back>
</article>
</pmc-articleset>